Silence Therapeutics (Silence Therapeutics) Cash-to-Debt : 198.24 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Silence Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 198.24.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Silence Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Silence Therapeutics's Cash-to-Debt or its related term are showing as below:

SLN' s Cash-to-Debt Range Over the Past 10 Years
Min: 109.9 Med: 5268.65 Max: No Debt
Current: 198.24

During the past 13 years, Silence Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 109.90. And the median was 5268.65.

SLN's Cash-to-Debt is ranked better than
82.78% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs SLN: 198.24

Silence Therapeutics Cash-to-Debt Historical Data

The historical data trend for Silence Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Silence Therapeutics Cash-to-Debt Chart

Silence Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

116.83

109.90

537.30

159.59

198.24

Silence Therapeutics Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															159.59	157.96	137.85	186.63	198.24

Competitive Comparison of Silence Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Silence Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silence Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Cash-to-Debt falls into.

Silence Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Silence Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	68.394	/	(0.227	+	0.118)
	=	198.24

Silence Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	68.394	/	(0.227	+	0.118)
	=	198.24

Silence Therapeutics (NAS:SLN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Silence Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Silence Therapeutics (Silence Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

SLNCF:USA XRP2:Germany

Address

72 Hammersmith Road, London, GBR, W14 8TH

Website

https://www.silence-therapeutics.com

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.